Assessment of a HER2 scoring system for gastric cancer: results from a validation study

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Histopathology

• Publication date

  2008-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2559.2008.03028.xPMID 18422971
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models

  2007cited by this paper
• Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm

  2006cited by this paper
• Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.

  2006cited by this paper
• Targeting EGFR in non-small-cell lung cancer.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Incidence and implications of HER2 and hormonal receptor overexpression in newly diagnosed metastatic breast cancer (MBC)

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

  2005influential reference
• Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab

  2005cited by this paper
• Coamplified and overexpressed genes at ERBB2 locus in gastric cancer

  2004cited by this paper
• HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues.

  2004cited by this paper
• Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit.

  2004cited by this paper
• Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer.

  2003cited by this paper
• Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

  2003cited by this paper
• HER2 testing in gastric cancer: molecular morphology and storage time-related changes in archival samples.

  2003cited by this paper
• Abnormal expression of E-cadherin, β-catenin, and c-erbB-2 in advanced gastric cancer: its association with liver metastasis

  2003cited by this paper
• Evaluation of HER-2 status in breast carcinoma by fluorescencein situ hybridization and immunohistochemistry

  2003cited by this paper
• Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry

  2003cited by this paper
• c-erb B-2 Expression Is Associated with Tumor Location and Venous Invasion and Influences Survival of Patients with Gastric Carcinoma

  2002cited by this paper
• Overexpression of c-erb-B2 proteins in tumor and non-tumor parts of gastric adenocarcinoma--emphasis on its relation to H. pylori infection and clinicohistological characteristics.

  2002cited by this paper
• Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin.

  2002cited by this paper
• Status of c‐erbB‐2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme‐linked immuno‐sorbent assay

  2002cited by this paper
• Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

  2002cited by this paper
• Overexpression of HER2/neu in solid tumours: an immunohistochemical survey

  2001cited by this paper
• The HER-2/neu Oncogene in Tumors of the Gastrointestinal Tract

  2001cited by this paper
• Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading-type and penetrating-type gastric carcinoma.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma.

  2000cited by this paper
• c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.

  2000cited by this paper
• Altered expression of beta-catenin and c-erbB-2 in early gastric cancer.

  2000cited by this paper
• 84th Meeting of the German Society of Pathology. Kiel, Germany, 7-10 June 2000. Abstracts.

  2000cited by this paper
• Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer.

  2000cited by this paper
• The Relationship between c-erbB-2 Oncogene Expression and Clinicopathological Factors in Gastric Cancer

  1999cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Expression of c-erbB-2 Oncoprotein in Gastric Carcinoma: Correlation with Histopathologic Characteristics and Analysis of Ki-67

  1999cited by this paper
• Prognostic factors in gastric cancer.

  1998cited by this paper
• ERBB2 oncogene in human breast cancer and its clinical significance.

  1998cited by this paper
• Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization.

  1998cited by this paper
• Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization.

  1997cited by this paper
• [Prognostic factors in gastric cancer].

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper

• Adequacy criteria and reporting for prognostic and predictive profiling of biopsies from gastrointestinal neoplasia: A position paper from the Italian group of gastrointestinal pathologists, section of Italian society of anatomic pathology and cytology (GIPAD-SIAPeC-IAP).

  2026cites this paper
• A composite biomarker based on early dynamic changes in lactate dehydrogenase and PD-L1 expression enhances outcome prediction for immunochemotherapy in HER2-negative advanced gastric cancer.

  2026cites this paper
• Making sense of TILs: recommendations for morphological assessment of tumour-infiltrating lymphocytes in gastro-oesophageal carcinoma: A report on behalf of the International Immuno-Oncology Biomarker Working Group.

  2026cites this paper
• An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1).

  2026cites this paper
• Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients

  2026cites this paper
• The tumor microenvironment in esophageal cancer and its association with clinical features and neoadjuvant treatment response

  2026cites this paper
• Molecular Testing for Intrahepatic Cholangiocarcinoma: What, When, How?

  2026cites this paper
• Diagnostic and Therapeutic Challenges Related to HER2 Heterogeneity in Gastric Cancer: Bridging Molecular Pathology and Clinical Decision-Making

  2026cites this paper
• Targeting HER2 in metastatic urothelial carcinoma: a contemporary review

  2025cites this paper
• A Phase II Trial of Trastuzumab Combined With Irinotecan in Patients With Advanced HER2-positive Chemotherapy-refractory Gastric Cancer (OGSG1203 HERBIS-5): Final Results

  2025cites this paper
• First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced Gastric and Gastroesophageal Junction Adenocarcinoma Patients with Poor Prognosis.

  2025cites this paper
• Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis

  2025cites this paper
• Histological and biomarker landscape of Claudin18.2-positive gastric and gastroesophageal junction cancers: a study of 937 cases.

  2025cites this paper
• BRCA2‐Related Hereditary Cancer Syndrome‐Associated Small Bowel Adenocarcinoma With Multiple BRCA2 Mutations: A Case Report and Review of the Literature

  2025cites this paper
• The antibody-drug conjugate sacituzumab govitecan (IMMU-132) represents a potential novel therapeutic strategy in cholangiocarcinoma.

  2025cites this paper
• HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy

  2025cites this paper
• Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study

  2025cites this paper
• Proportional Correlation Between Systemic Inflammation Response Index and Gastric Cancer Recurrence Time: A Retrospective Study

  2025cites this paper
• Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos

  2025cites this paper
• Function of ERbB2 in Cancer and the development of tailored treatment for Gastric Cancer: Signaling routes to treatment approaches

  2025cites this paper
• Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2

  2025cites this paper
• HER2 testing: evolution and update for a companion diagnostic assay

  2025cites this paper
• Evaluation of Her2 Positivity in Gastric Cancer Using Two Different Methods: A Prospective Study

  2025cites this paper
• Problematic aspects of assessing predictive markers for gastric cancer based on endoscopic biopsy samples. Review

  2025cites this paper
• Development of Treatment Strategies for Advanced HER2-positive Gastric Cancer: Insights from Clinical Trials.

  2025cites this paper
• Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: current insights and future prospects

  2025cites this paper
• Expression of programmed cell death ligand 1 protein and other biomarkers in patients with gastric cancer and gastroesophageal junction cancer: a retrospective single centre study in Brazil

  2025cites this paper
• Molecular insights into HER2/ERBB2 amplification and carcinogenesis in gallbladder cancer associated with pancreaticobiliary maljunction

  2025cites this paper
• HER2 Status in Gastric and Gastroesophageal Carcinomas: Evaluation of Histopathological Fingings, Paired ResectionBiopsy Specimens, and the Effect of Neoadjuvant Therapy: A Single Center Study.

  2025cites this paper
• Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight

  2025cites this paper
• Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• An evaluation of known predictive biomarkers for gastric cancer

  2025cites this paper
• Trastuzumab significantly improves survival in resectable HER-2 positive gastric cancer: A retrospective study

  2025cites this paper
• Advances in Targeting HER2 across Cancer Subtypes - A Pan-tumor Approach.

  2025cites this paper
• Prevalence of HER2 expression and its association with clinicopathological parameters in gastric and gastroesophageal junction adenocarcinoma: A 10-year experience of an academic center

  2025cites this paper
• Ramucirumab and paclitaxel in second or greater lines of therapy in patients with HER2-positive gastroesophageal cancer: a single center study

  2025cites this paper
• Safety and Efficacy of Anti–Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review

  2025cites this paper
• Evolution of HER2-low expression from primary to paired metastatic gastric cancer lesions

  2025cites this paper
• Targeted therapies in primary vaginal cancer

  2025cites this paper
• HER2, HER3 and mismatch repair protein expression in stage IV small bowel adenocarcinoma: results from a multicenter series.

  2025cites this paper
• Isolated tumor cell clusters (ITC) in lymph nodes and PD-L1 expression on tumor-associated immune cells are prognostic factors for microsatellite instable-high gastric cancers

  2025cites this paper
• Grossly visible non-invasive neoplasm of the gallbladder: method of classification and its relationship to pyloric gland adenoma.

  2025cites this paper
• Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression.

  2025cites this paper
• Comparative analysis of the results of radiation diagnostics and immunohistochemical examination of patients with gastric cancer

  2025cites this paper
• HER2-low across solid tumours: different incidences and definitions.

  2025cites this paper
• Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer

  2025cites this paper
• Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization

  2025cites this paper
• Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients

  2025cites this paper
• Expression of Her-2 and Ki-67 in Gastric Cancer Formalin Fixed Paraffin Embedded Tissue Blocks and Their Correlation with Histological Grades at the Uganda Cancer Institute Pathology Laboratory

  2024influential citation
• Tissue Biomarkers in Gastric Cancer Treatment: Present and Future

  2024cites this paper
• The Relationship Between HER2 Status Acquired From Pathological Data and Metabolic Parameters From Pre-treatment [18F]FDG PET/CT in Gastric Adenocarcinomas.

  2024cites this paper
• The addition of PD-1 inhibitor overcame trastuzumab resistance in patients with HER2 positive, PD-L1 negative metastatic gastric cancer: Case report and review of literature

  2024cites this paper
• Molecular testing of gastrointestinal tumours

  2024cites this paper
• Advancements and challenges in gastric cancer: epidemiology, biomarkers, and therapeutic strategies

  2024cites this paper
• A Gene Expression Signature that Predicts Gastric Cancer Sensitivity to PARP Inhibitor Therapy

  2024cites this paper
• Association of PD-L1 positivity with Epstein Barr virus infection and microsatellite instability in gastric carcinomas with lymphoid stroma

  2024cites this paper
• Her2 positive metastatic gastric cancer

  2024cites this paper
• HER2 in Gastric Cancer: A Comprehensive Analysis Combining Meta-Analysis and DCE-MRI Radiomics

  2024cites this paper
• HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment

  2024cites this paper
• Evidence for Unified Assessment Criteria of HER2 IHC in Colorectal Carcinoma.

  2024cites this paper
• Clinicopathological Implication of HER2/neu Expression in Carcinoma Stomach

  2024cites this paper
• Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies

  2024cites this paper
• Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort

  2024cites this paper
• Prognostic significance of low HER2 expression in gastric cancer: a retrospective, single-center analysis

  2024cites this paper
• Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment.

  2024cites this paper
• Clinicopathologic Characteristics of Trop Family Proteins (Trop-2 and EpCAM) in Gastric Carcinoma

  2024cites this paper
• Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma: A comparative analysis and biomarker study

  2024cites this paper
• HER2 immunohistochemical expression and its association with clinicopathological features of gastric adenocarcinoma in Uganda.

  2024cites this paper
• Efficacy and safety of anti-programmed death-1 antibody-based combination therapy in advanced or metastatic gastric or gastroesophageal junction cancer in Chinese patients: A real-world study

  2024cites this paper
• Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach.

  2024cites this paper
• Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework

  2024cites this paper
• HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains

  2024cites this paper
• Prognostic and predictive role of YKL-40 in anal squamous cell carcinoma: a serological and tissue-based analysis in a multicentric cohort

  2024cites this paper
• Implementing an integrated molecular classification for gastric cancer from endoscopic biopsies using on-slide tests

  2024cites this paper
• A Clinicopathological Study of Oesophageal Malignancies With Special Reference to Immunohistochemical Expression of HER2/Neu

  2024cites this paper
• RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification

  2024cites this paper
• Histopathological Study of Gastric Adenocarcinoma with Special Reference to Expression of HER2/neu and Ki-67 Assessed by Immunohistochemistry

  2024cites this paper
• State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies

  2024cites this paper
• Prediction of a Panel of Programmed Cell Death Protein-1 (PD-1) Inhibitor–Sensitive Biomarkers Using Multiphase Computed Tomography Imaging Textural Features: Retrospective Cohort Analysis

  2024influential citation
• HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments

  2024cites this paper
• Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice

  2024cites this paper
• Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer

  2024cites this paper
• Recent updates of chemotherapy in advanced gastric cancer

  2024cites this paper
• Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma

  2024cites this paper
• Quantitative proteomic analysis of HER2 protein expression in PDAC tumors

  2024cites this paper
• Advances in Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Upper Gastrointestinal Cancers.

  2024cites this paper
• Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.

  2024cites this paper
• Current and Future Biomarkers in Esophagogastric Adenocarcinoma

  2024influential citation
• HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls

  2024cites this paper
• A case of pathological complete regression in combined modality treatment of resectable her2/ neu-positive gastric cancer

  2024cites this paper
• C-ERB B2 EXPRESSION IN COLORECTAL CARCINOMA; ITS RELATIONSHIP WITH TUMOR GRADE AND OTHER PROGNOSTIC FACTORS

  2024cites this paper
• Fourth-line Trastuzumab deruxtecan in HER2-positive metastatic gastric cancer

  2024cites this paper
• HER-2 directed therapies across gastrointestinal tract cancers - A new frontier.

  2024cites this paper
• Global trends in indocyanine green fluorescence navigation in the field of gastric cancer: bibliometrics and knowledge atlas analysis

  2023cites this paper
• Expression of Her2-Neu in Primary Gastric and Gastroesophageal Adenocarcinoma: An Experience from a Tertiary Center in South India

  2023cites this paper
• p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab

  2023cites this paper
• The function and immune role of cuproptosis associated hub gene in Barrett's esophagus and esophageal adenocarcinoma.

  2023cites this paper
• The relationship between brain metastasis and HER2 expression status in gastric cancer

  2023cites this paper
• Nestin overexpression reduces the sensitivity of gastric cancer cells to trastuzumab

  2023cites this paper
• Comparison of human epidermal growth factor receptor 2 and cancer stem cell markers like CD44 and CD133 expressions with clinicopathological parameters in gastric cancer

  2023cites this paper